Skip to main content
. 2023 Aug 23;9(34):eadg6693. doi: 10.1126/sciadv.adg6693

Fig. 3. MYO1B is strongly expressed in NB with MYCN amplification.

Fig. 3.

(A) Expression profile of MYO1B in human cancer cell lines plotted based on data from the DepMap database_Expression Public 21Q4. (B) The expression profile of MYO1B in pediatric cancers in the TARGET project cohort was extracted from cBioPortal database. (C) Comparison of MYO1B mRNA levels in four cohorts of NB patient samples and nontumor adrenal gland samples. Plots were derived from the R2 database. (D) Statistics (left panel) and representative images (right panel) showing MYO1B expression evaluated by immunohistochemistry (IHC) in MNA and MNA+ NB. (E and F) Protein expression of the indicated markers in a panel of NB cell lines was assessed by immunoblotting, and correlation among the markers normalized to an actin loading control was analyzed (F). (G) Confocal microscopic analysis of the expression level of MYO1B and its colocalization with actin cytoskeleton as assessed by TRITC-phalloidin staining. Differences between groups were determined by two-tailed unpaired Student’s t test. ***P < 0.001. Fisher’s exact test was used to determine the associations between two categorical variables in two groups. Pearson coefficient analysis was performed to determine correlations between two variables.